Literature DB >> 32394397

A candidate gene study of intermediate histopathological phenotypes in HIV-associated neurocognitive disorders.

Andrew J Levine1, Virawudh Soontornniyomkij2, Eliezer Masliah3, Janet S Sinsheimer4,5, Sarah S Ji5, Steve Horvath5,6, Elyse J Singer7, Asha Kallianpur8, David J Moore2.   

Abstract

HIV-associated neurocognitive disorders (HAND) describe a spectrum of neuropsychological impairment caused by HIV-1 infection. While the sequence of cellular and physiological events that lead to HAND remains obscure, it likely involves chronic neuroinflammation. Host genetic markers that increase the risk for HAND have been reported, but replication of such studies is lacking, possibly due to inconsistent application of a behavioral phenotype across studies. In the current study, we used histopathologic phenotypes in order to validate putative risk alleles for HAND. The National NeuroAIDS Tissue Consortium, a longitudinal study of the neurologic manifestations of HIV. Data and specimens were obtained from 175 HIV-infected adults. After determining several potential covariates of neurocognitive functioning, we quantified levels of six histopathological markers in the frontal lobe in association with neurocognitive functioning: SYP, MAP 2, HLA-DR, Iba1, GFAP, and β-amyloid. We then determined alleles of 15 candidate genes for their associations with neurocognitive functioning and histopathological markers. Finally, we identified the most plausible causal pathway based on our data using a multi-stage linear regression-based mediation analysis approach. None of the genetic markers were associated with neurocognitive functioning. Of the histopathological markers, only MAP 2 and SYP were associated with neurocognitive functioning; however, MAP 2 and SYP did not vary as a function of genotype. Mediation analysis suggests a causal pathway in which presynaptic degeneration (SYP) leads to somatodendritic degeneration (MAP 2) and ultimately neurocognitive impairment. This study did not support the role of host genotype in the histopathology underlying HAND. The findings lend further support for synaptodendritic degeneration as the proximal underlying neuropathological substrate of HAND.

Entities:  

Keywords:  Genetic; HIV-associated neurocognitive disorder; Histopathology; NeuroAIDS; Neuropathology; Synaptodendritic

Mesh:

Substances:

Year:  2020        PMID: 32394397      PMCID: PMC7442707          DOI: 10.1007/s13365-020-00846-z

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  67 in total

1.  Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood-brain barrier damage.

Authors:  Davide Fiore Bavaro; A Calamo; L Lepore; C Fabrizio; A Saracino; G Angarano; L Monno
Journal:  Infection       Date:  2019-01-16       Impact factor: 3.553

Review 2.  Aging and Neurocognitive Functioning in HIV-Infected Women: a Review of the Literature Involving the Women's Interagency HIV Study.

Authors:  David E Vance; Leah H Rubin; Victor Valcour; Drenna Waldrop-Valverde; Pauline M Maki
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

3.  Interactive effects of neurocognitive impairment and substance use on antiretroviral non-adherence in HIV disease.

Authors:  Nicholas S Thaler; Philip Sayegh; Michelle S Kim; Steven A Castellon; Charles H Hinkin
Journal:  Arch Clin Neuropsychol       Date:  2015-01-14       Impact factor: 2.813

Review 4.  HIV-associated neurocognitive disorder.

Authors:  David B Clifford; Beau M Ances
Journal:  Lancet Infect Dis       Date:  2013-11       Impact factor: 25.071

5.  HIV Protease Inhibitors Alter Amyloid Precursor Protein Processing via β-Site Amyloid Precursor Protein Cleaving Enzyme-1 Translational Up-Regulation.

Authors:  Patrick J Gannon; Cagla Akay-Espinoza; Alan C Yee; Lisa A Briand; Michelle A Erickson; Benjamin B Gelman; Yan Gao; Norman J Haughey; M Christine Zink; Janice E Clements; Nicholas S Kim; Gabriel Van De Walle; Brigid K Jensen; Robert Vassar; R Christopher Pierce; Alexander J Gill; Dennis L Kolson; J Alan Diehl; Joseph L Mankowski; Kelly L Jordan-Sciutto
Journal:  Am J Pathol       Date:  2017-01       Impact factor: 4.307

6.  The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease.

Authors:  S Morgello; B B Gelman; P B Kozlowski; H V Vinters; E Masliah; M Cornford; W Cavert; C Marra; I Grant; E J Singer
Journal:  Neuropathol Appl Neurobiol       Date:  2001-08       Impact factor: 8.090

7.  Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study.

Authors:  J C McArthur; D R Hoover; H Bacellar; E N Miller; B A Cohen; J T Becker; N M Graham; J H McArthur; O A Selnes; L P Jacobson
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

8.  Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Authors:  Luis B Tovar-y-Romo; Namandjé N Bumpus; Daniel Pomerantz; Lindsay B Avery; Ned Sacktor; Justin C McArthur; Norman J Haughey
Journal:  J Pharmacol Exp Ther       Date:  2012-09-13       Impact factor: 4.030

9.  Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV.

Authors:  Andrew J Levine; Virawudh Soontornniyomkij; Cristian L Achim; Eliezer Masliah; Benjamin B Gelman; Janet S Sinsheimer; Elyse J Singer; David J Moore
Journal:  J Neurovirol       Date:  2015-12-04       Impact factor: 2.643

10.  HIV-1 Tat protein promotes neuronal dysregulation by inhibiting E2F transcription factor 3 (E2F3).

Authors:  Maryline Santerre; Asen Bagashev; Laura Gorecki; Kyle Z Lysek; Ying Wang; Jenny Shrestha; Fabiola Del Carpio-Cano; Ruma Mukerjee; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2018-12-27       Impact factor: 5.157

View more
  1 in total

1.  An exploratory pilot study on the involvement of APOE, HFE, C9ORF72 variants and comorbidities in neurocognitive and physical performance in a group of HIV-infected people.

Authors:  Isabella Zanella; Eliana Zacchi; Chiara Fornari; Benedetta Fumarola; Melania Degli Antoni; Daniela Zizioli; Eugenia Quiros-Roldan
Journal:  Metab Brain Dis       Date:  2022-03-30       Impact factor: 3.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.